Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor
Gang Zhao(Sichuan University), Philip R. Kym(AbbVie (United States)), Zhi Su(Sichuan Normal University), Jennifer C. Freeman(Abbott Fund), David W. A. Beno(Abbott Fund), Andrew J. Souers(AbbVie (United States)), Matthew M. Ravn(AbbVie (United States)), Kennan C. Marsh(AbbVie (United States)), Yau Yi Lau(Pennsylvania State University), Sevan Brodjian(Abbott Fund), Brian A. Droz(Abbott Fund), Mathew M. Mulhern(Research International (United States)), Andrew S. Judd(AbbVie (United States)), Gilbert Diaz(Abbott Fund), Regina M. Reilly(Abbott (United States)), Ju Gao(Sichuan University), Kenneth M. Engstrom(Abbott Fund), Seble Wagaw(Abbott Fund), Brian D. Dayton(AbbVie (United States)), Xiaojun Wang(Academy of Medical Sciences), Christine A. Collins(AbbVie (United States)), Rajesh R. Iyengar(Abbott Fund), Hing L. Sham(University of Nottingham Ningbo China), H. Doug Falls(Abbott Fund), Michael E. Brune(Abbott Fund), Martin J. Voorbach(AbbVie (United States)), Dennis G. Fry(Abbott Fund), Nelson Grihalde(Abbott Fund)
Cited by 140
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541